Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: Comparison of 2 dosing strategies in dual-refractory disease

Blood

Volumn 118, Issue 11, 2011, Pages 2970-2975

  Lacy, Martha Q ^a   Allred, Jacob B ^b   Gertz, Morie A ^a   Hayman, Suzanne R ^a   Short, Kristen Detweiler ^a   Buadi, Francis ^a   Dispenzieri, Angela ^a   Kumar, Shaji ^a   Greipp, Philip R ^a   Lust, John A ^a   Russell, Stephen J ^a   Dingli, David ^a   Zeldenrust, Steven ^a   Fonseca, Rafael ^c   Bergsagel, P Leif ^c   Roy, Vivek ^d   Stewart, A Keith ^c   Laumann, Kristina ^b   Mandrekar, Sumithra J ^b   Reeder, Craig ^c   Rajkumar, S Vincent ^a   Mikhael, Joseph R ^c   more..

^a Mayo Clinic   (United States)

^b MAYO CLINIC   (United States)

^c MAYO CLINIC   (United States)

^d MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BILIRUBIN; BORTEZOMIB; DEXAMETHASONE; LENALIDOMIDE; POMALIDOMIDE;

ADULT; AGED; AGITATION; ANEMIA; ANOREXIA; ANXIETY; ARTICLE; BACKACHE; BILIRUBIN BLOOD LEVEL; BRADYCARDIA; CLINICAL ARTICLE; COHORT ANALYSIS; CONFUSION; CORTICOSTEROID THERAPY; DEEP VEIN THROMBOSIS; DIARRHEA; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; DYSPEPSIA; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FRACTURE; HEART ARRHYTHMIA; HUMAN; HYPERCALCEMIA; HYPERGLYCEMIA; INSOMNIA; KIDNEY FAILURE; LEUKOPENIA; LYMPHOCYTE COUNT; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA AND VOMITING; NEUTROPHIL COUNT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RASH; SENSORY NEUROPATHY; SIDE EFFECT; SWEATING; THROMBOCYTE COUNT; THROMBOSIS; THROMBOSIS PREVENTION; TREATMENT FAILURE; TREATMENT RESPONSE; TREMOR; UPPER RESPIRATORY TRACT INFECTION;

EID: 80052937408     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-04-348896     Document Type: Article

References (10)

1. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341(21):1565-1571.
2. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111(5):2516- 2520.
3. Schey SA, Fields P, Bartlett JB, et al. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol. 2004;22(16):3269-3276. (Pubitemid 41103682)
4. Streetly MJ, Gyertson K, Daniel Y, Zeldis JB, Kazmi M, Schey SA. Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation. Br J Haematol. 2008;141(1):41-51. (Pubitemid 351350609)
5. Lacy MQ, Hayman SR, Gertz MA, et al. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol. 2009;27(30):5008-5014.
6. Lacy MQ, Hayman SR, Gertz MA, et al. Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). Leukemia. 2010;24(11):1934-1939.
7. Richardson PG, Siegel D, Baz R, et al. A phase 1/2 multi-center, randomized, open label dose escalation study to determine the maximum tolerated dose, safety, and efficacy of pomalidomide alone or in combination with low-dose dexamethasone in patients with relapsed and refractory multiple myeloma who have received prior treatment that includes lenalidomide and bortezomib [abstract]. Blood (ASH Annual Meeting Abstracts). 2010;116(21):Abstract 864.
8. Leleu X, Attal M, Moreau P, et al. Phase 2 study of 2 modalities of pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. IFM 2009-02 [abstract]. Blood (ASH Annual Meeting Abstracts). 2010;116(21):Abstract 859.
9. Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia. 2009;23(1):3-9.
10. Kumar S, Blade J, Crowley J, et al. Natural history of multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter International Myeloma Working Group Study [abstract]. Blood (ASH Annual Meeting Abstracts). 2009;114(22):Abstract 2878.